BioSpace News Archive

Make-A-Wish chapters and affiliates worldwide celebrate making the impossible possible for children with critical illnesses

OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will host its latest State of the Science Summit™ on breast cancer on Wednesday, April 10, from 5-9 p.m. at the DoubleTree by Hilton Hotel Dallas Near the Galleria, in Texas.

The Company’s earnings release will be available in the Investors section of the Company’s website.

William “BJ” Jones joins Biohaven as Chief Commercial Officer, Migraine and Common Diseases

The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research Annual Meeting 2019 in Atlanta.

Avivagen Inc. is pleased to announce that it has begun to explore the combination of Avivagen’s proprietary OxC-beta™ product with licensed cannabis products.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25 before the market opens.

EvoNexus, Southern California’s leading startup incubator with locations in San Diego and Irvine, in partnership with EMD Performance Materials, the North America high-tech materials business of Merck KGaA, Darmstadt, Germany, today announced it has launched an open application round in search of early stage companies with emerging technologies and use cases relevant to EMD Performance Materials’ core business

Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment. Results from a phase 1b clinical trial of a new experimental glioblastoma vaccine developed by Jefferson Health and Imvax, show the treatment was tolerated well by patients, slowed tumor recurrence, and prolonged patient survival.

Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting pre-clinical data from ongoing research of RGX-019,